The association of vascular risk factors with visual loss in giant cell arteritis
The association of vascular risk factors with visual loss in giant cell arteritis
复制标题
DOI：
10.1093/rheumatology/kew397
复制
发表时间：
2017-04-01
期刊：
影响因子：
5.5
通讯作者：
Watts, Richard A.
中科院分区：
文献类型：
--
作者：
Yates, Max;MacGregor, Alex J.;Watts, Richard A.
Objective.失明是公认的GCA并发症;然而，这种并发症的频率和风险因素尚未确定。本研究的目的是利用一个大型的国际队列研究GCA患者失明的发生率和决定因素。该分析是在血管炎诊断和分类标准研究中招募的受试者中进行的。该研究捕获了连续的患者向诊所医生就诊。新发失明在诊断后6个月通过完成血管炎损伤指数进行评估。采用Logistic回归分析方法，分析致盲与临床变量之间的关系。在来自26个国家的433例GCA患者中，7.9%在6个月时至少有一只眼睛失明。在基线时确定的6个月失明的危险因素包括流行性脑卒中[OR = 4.47，95%CI：1.30，15.41]和周围血管疾病[OR = 10.44，95%CI：2.94，37.03]。这是迄今为止对GCA患者进行的最大规模的研究，证实了失明仍然是疾病的常见并发症，并与已确定的血管疾病有关。试验注册：ClinicalTrials.gov，ext-link-type=“uri”xlink：href=”http://clinicaltrials.gov“> http：//clinicaltrials.gov，NCT 01066208。
Objective. Blindness is a recognized complication of GCA; however, the frequency of and risk factors for this complication have not been firmly established. The aim of this study was to examine the incidence and determinants of blindness in patients with GCA, using a large international cohort.Methods. The analysis was conducted among subjects recruited into the Diagnosis and Classification Criteria in Vasculitis Study. The study captures consecutive patients presenting to clinic-based physicians. New-onset blindness was assessed 6 months after diagnosis by completion of the Vasculitis Damage Index. Logistic regression analysis was used to assess the association between blindness and clinical variables.Results. Of 433 patients with GCA from 26 countries, 7.9% presented with blindness in at least one eye at 6 months. Risk factors identified at baseline for blindness at 6 months were identified and included prevalent stroke [odds ratio (OR) = 4.47, 95% CI: 1.30, 15.41] and peripheral vascular disease (OR = 10.44, 95% CI: 2.94, 37.03).Conclusion. This is the largest study to date of subjects with incident GCA and confirms that blindness remains a common complication of disease and is associated with established vascular disease.Trial registration: ClinicalTrials.gov, ext-link-type="uri" xlink:href="http://clinicaltrials.gov">http://clinicaltrials.gov, NCT01066208.